Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

NCT05834855 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases

Interventions

DRUG: Rituximab

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]